# Multus Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/multus-biotechnology

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.multus.bio
- Total disclosed funding: $11M
- Latest round: Series A (Nov 16, 2022)
- Investors on record: 9

## About

Based in the UK, Multus Biotechnology Limited develops innovative animal-free media formulations for bioprocesses, targeting the cultivated meat and advanced therapeutics sectors.Multus Biotechnology Limited, founded in 2019 in London, UK, specializes in creating animal-free growth media to replace traditional fetal bovine serum in bioprocessing. The company has raised USD 7.14 mn in funding through 6 deals. The most recent funding round, a Grant amounting to USD 2.5 mn, was secured on January 16, 2023, from Innovate UK. The company was established by co-founders Cai Linton, Evan Whooley, Kevin Pan, Ram Pillai, and Réka Trón, with Cai Linton serving as the CEO.Multus Biotechnology specializes in developing and supplying animal-free media formulations designed to replace traditional fetal bovine serum (FBS) in bioprocesses, particularly for the cultivated meat and advanced therapeutics sectors. Their core product offerings include optimized media solutions that support cell growth and proliferation, thereby facilitating the scale-up of biomanufacturing processes. These media formulations are tailored for specific cell types, focusing on adherent cells, enhancing the efficiency and cost-effectiveness of bioprocessing. Multus serves a diverse clientele, including cultivated meat companies like Quest Meat, Roslintech, and Jellatech, primarily in the United Kingdom and extending their reach to the broader European market.Multus Biotechnology generates revenue through B2B partnerships and customized media supply agreements with various companies in the cultivated meat and cell therapy sectors. Their business model involves direct sales transactions, with clients entering agreements for tailored media formulations to meet specific research and development needs. The pricing structure accommodates the unique requirements of clients, ensuring that media formulations are accessible and affordable. These transactions include comprehensive support, clear preparation instructions, and ongoing communication to address client needs, supported by a reliable supply chain management system.In January 2023, Multus Biotechnology Limited raised USD 2.5 mn in grant funding from Innovate UK, part of a larger USD 9.5 mn Series A and grant funding round. The company plans to use this funding to establish a production plant in the UK, enhancing their capabilities in developing new products for the cultivated meat industry. Expansion into new markets within Europe is also targeted, with specific regions and timelines yet to be announced.

## Funding rounds

- Series A, Nov 16, 2022, $8.5M — SOSV, Big Idea Ventures, Asahi Kasei Corporate Venture Capital, Mandi Ventures, State Street Digital, SynBioVen
- Seed, Jul 19, 2021, $2.2M — SOSV, Marinya Capital, Zero Carbon Capital
- Seed, May 5, 2020 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Marinya Capital — Seed
- Zero Carbon Capital (https://capitalatlas.ai/funds/zero-carbon-capital) — Seed
- Big Idea Ventures (https://capitalatlas.ai/funds/big-idea-ventures) — Series A
- Asahi Kasei Corporate Venture Capital — Series A
- Mandi Ventures (https://capitalatlas.ai/funds/mandi-ventures) — Series A
- State Street Digital (https://capitalatlas.ai/funds/state-street-digital) — Series A
- SynBioVen (https://capitalatlas.ai/funds/synbioven) — Series A